Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls

[1]  P. Rosenberg,et al.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort , 2016, Cancer.

[2]  J. Schiffman,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. , 2016, The Lancet. Oncology.

[3]  C. Bonaïti‐pellié,et al.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  David M. Thomas,et al.  Surveillance recommendations for patients with germline TP53 mutations , 2015, Current opinion in oncology.

[5]  P. Hainaut,et al.  18F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome , 2015, Front. Oncol..

[6]  G. Rosen,et al.  Prognostic Factors and Survival in Patients Treated Surgically for Recurrent Metastatic Uterine Leiomyosarcoma , 2014, International journal of surgical oncology.

[7]  David M. Thomas,et al.  Li-Fraumeni syndrome: cancer risk assessment and clinical management , 2014, Nature Reviews Clinical Oncology.

[8]  M. Leach,et al.  MRI breast screening in high-risk women: cancer detection and survival analysis , 2014, Breast Cancer Research and Treatment.

[9]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[10]  M. Mathieu,et al.  Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome , 2010, Radiation oncology.

[11]  M. Olivier,et al.  Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect , 2010, Human mutation.

[12]  Z. Saifudeen,et al.  p53 regulates metanephric development. , 2009, Journal of the American Society of Nephrology : JASN.

[13]  Caterina Giannini,et al.  Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. , 2009, Neuro-oncology.

[14]  R. Warren,et al.  Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[15]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Stockman.  F18-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome , 2009 .

[17]  D. Evans,et al.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes , 2005, Journal of Medical Genetics.

[18]  P. Pharoah,et al.  Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.

[19]  J. Varley.  Germline TP53 mutations and Li‐Fraumeni syndrome , 2003, Human mutation.

[20]  C. Fegan,et al.  Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol , 2003, Cell cycle.

[21]  Z. Saifudeen,et al.  A role for p53 in terminal epithelial cell differentiation. , 2002, The Journal of clinical investigation.

[22]  J. Fraumeni,et al.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  J. Fraumeni,et al.  Multiple primary cancers in families with Li-Fraumeni syndrome. , 1998, Journal of the National Cancer Institute.

[24]  D. Evans,et al.  Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. , 1997, Cancer research.

[25]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[26]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.